All News
ACR Applauds Prior Authorization Rule
ACR
The American College of Rheumatology (ACR), on behalf of over 9,100 rheumatologists and rheumatology professional team members, applauds the Centers for Medicare and Medicaid Services (CMS) for finalizing its Advancing Interoperability and Improving Prior Authorization Processes for Medicare Adva
Read Article
Severe Hypocalcemia Risk with Denosumab and CKD Patients
On 1-19-2024, the Food and Drug Administration (FDA) issued a Drug Safety Communication about the risk of severe hypocalcemia in chronic kidney disease (CKD) patients taking denosumab for osteoporosis, with an accentuated risk in older women who are dialysis-dependent.
This report is an update to their November 2022 investigation, the results of a related study being recently reported in JAMA.
QD Clinic - RA, SSZ, & MI
RA with a myocardial inflarction - which DMARD?
https://t.co/9o83xedJ3j https://t.co/P5jmZAZ9rt
Dr. John Cush RheumNow ( View Tweet)
Join us this weekend! More than 25 sessions on topics ranging from spondyloarthritis, PsA, vasculitis and lupus to JAK inhibitors, RA, artificial intelligence and myositis. CME and MOC offered. Learn more about our program and registration options today!
https://t.co/Iac2T2Kohs https://t.co/zu1WJLOcmh
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate Nodulosis
How good (or not) are rheumatologists and what to do about MTX nodulosis?
https://t.co/Ot9UfpH68N https://t.co/JQ2AtuE7NV
Dr. John Cush RheumNow ( View Tweet)
11-yr French study of #RA Pregnancies: more adverse Preg outcomes in RA, esp w/ active Dz. 11.8K RA vs 10.4 million non-RA Pregs. 75% live births in RA. RA had more preterm(aOR 1.84), low birth wt (1.65), C-Sect (1.46), hospz (1.30), & prematurity (2.02)https://t.co/v9CmiPkIBG https://t.co/S0siiuG0oZ
Dr. John Cush RheumNow ( View Tweet)
Mexico survey of 250 RA pts -- 92% used complementary (CAM) therapies - mostly: herbals (65%), homeopathy (64%), cannabis derivatives (51%). Poor DMARD adherence assoc w/ age (p=0.019), comorbidities (p=0.047), CAM use (p = 0.042) (OR 2.84) https://t.co/EGxyIVCMnk https://t.co/jjF5cH53we
Dr. John Cush RheumNow ( View Tweet)
FDA Safety Warning: denosumab now has a Boxed Warning for risk of severe hypocalcemia in CKD pts taking Prolia (usually seen 2-10 wks post injx). Pts may or may not be symptomatic. CKD pts should have Ca and Creatinine monitored. https://t.co/tGiG35cOnv https://t.co/ITOZneGKtb
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists and the Early Diagnosis of Spondyloarthritis
SPACE study of adults referred to rheumatology with less than 2 years of chronic back pain (CBP), shows that only one-third can be reliably diagnosed with axial spondyloarthritis (axSpA).
https://t.co/EwrrunyZs7. https://t.co/T0OqlsuU2P
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists: What is your preferred MOA/Drug in treating Psoriatic Arthritis?
Dr. John Cush RheumNow ( View Tweet)
Rituximab Efficacy in MAINRITSAN Long-Term Studies
https://t.co/z16uMDihV4 https://t.co/BaWFcwDbYL
Dr. John Cush RheumNow ( View Tweet)
Sodium Channels, Carbemazepine and Osteoarthritis Progression
A study published in Nature suggests that therapies affecting sodium channels could be employed to treat osteoarthritis.
https://t.co/hmzKsgb3gA https://t.co/WVgk8nD4ne
Dr. John Cush RheumNow ( View Tweet)
You can still attend RheumNow Live!
Below is a preview of one of our "STEP" talks - by Mike Putman, MD, who brings his vast knowledge to the forefront, shedding light on Myths & Mistakes on ANCA-Associated Vasculitis.
https://t.co/LzcVytLDij
Register: https://t.co/NWXKNhQzc5 https://t.co/ogAfTtH5Nk
Dr. John Cush RheumNow ( View Tweet)
New download available!
Seasonal Flu Vaccination in RA Patients
https://t.co/tNwgUVoG7Z https://t.co/P1UqPU57WU
Dr. John Cush RheumNow ( View Tweet)
IL-17 pathway as a target in giant cell arteritis - full read review of pathogenic role of IL-17 and Th17 cells, in #GCA; backed up by the phase II proof-of-principle TiTAIN study showing potential efficacy of secukinumab in GCA pts https://t.co/MThzw2joGO https://t.co/PmrJjf9C3a
Dr. John Cush RheumNow ( View Tweet)
2023 EULAR Non-pharmacological Management of Hip and Knee Osteoarthritis: 2023 update
EULAR has published the 2023 updated recommendations for the optimal non-pharmacological management of hip and knee osteoarthritis (OA).
https://t.co/OjmdAnRWtl https://t.co/gfWYopEgtt
Links:
Dr. John Cush RheumNow ( View Tweet)
Japanese retrospective study compared RA pts on JAK inhib vs bDMARDs (n=62 ea) having orthopedic surgery; JAKi- pts had more postoperative flares (29% v 12%, P=.01), esp if JAKi held >11d (p.04). No diff in other postop complications https://t.co/NVY1Oajdve https://t.co/fwc9KWYZ9l
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort compared 6147 new PsA pts vs 23,999 contros PsA. The uveitis risk was significantly higher in PsA (adj HR 2.38). Uveitis risk in PsA higher with prior uveitis (adj OR 136.4) and etanercept Rx (aOR 2.57). 106/107 Rx w/ topical steroids https://t.co/YVzIzSOaiB https://t.co/YORU8cQrAx
Dr. John Cush RheumNow ( View Tweet)
Increased CV Comorbidity in Dermatomyositis
A cohort study suggest that patients with dermatomyositis (DM) are at an increased risk for multiple comorbidities, including chronic kidney and cardiovascular disease,
https://t.co/bYvd5AhqSl https://t.co/4y4kjYhTm3
Dr. John Cush RheumNow ( View Tweet)
Hepatitis B Virus Reactivation is possible w/ immunosuppression- most (>10%) w/ w/ Rituximab & stem cell transplants. If HBsAg positive, pts should recv anti-viral prophylaxis; HBsAg− individuals should be evaluated on a case-by-case basis https://t.co/7JKorgWbYr https://t.co/RdW65u5KDR
Dr. John Cush RheumNow ( View Tweet)
